scholarly journals Long-Term Protection After Fractional-Dose Yellow Fever Vaccination

2019 ◽  
Vol 171 (2) ◽  
pp. 145 ◽  
Author(s):  
Annelies Wilder-Smith ◽  
Alan Barrett ◽  
Kirsten Vannice ◽  
Joachim Hombach
Keyword(s):  
Yellow Fever ◽  
Fractional Dose ◽  
Yellow Fever Vaccination

Fractional-dose yellow fever vaccination: an expert review

2019 ◽  
Vol 26 (6) ◽  
Author(s):  
Anna H E Roukens ◽  
Leo G Visser
Keyword(s):  
Yellow Fever ◽  
Yellow Fever Virus ◽  
World Health ◽  
Yellow Fever Vaccine ◽  
Short Term ◽  
Protective Response ◽  
Fractional Dose ◽  
Dose Sparing ◽  
Yellow Fever Vaccination

Abstract Rationale for review: The global yellow fever vaccine supply is insufficient to provide full-dose vaccination to millions threatened by outbreaks. Given the excess of live-attenuated 17D yellow fever virus in the current single dose vials, dose sparing would increase available vaccine doses manifold. Fractional-dose yellow fever vaccination is now accepted as an emergency solution, as short-term protection has been confirmed in an outbreak situation in the Democratic Republic of Congo, but broader application of this dose-sparing strategy is still not recommended. In this review, important knowledge gaps that hamper this application such as long-term protection after fractional-dose vaccination, safety, comparability across different genetic backgrounds and different World Health Organization-licensed yellow fever vaccines and immunogenicity in infants are addressed. Main findings: Recently, published results on long-term protection after fractional-dose vaccination in healthy young volunteers indicate that if a person mounts a protective response shortly after vaccination, the protective response will persist for 10 years and possibly longer. It also appears that fractional-dose vaccination does not elicit more serious adverse events than standard dose vaccination. Short-term immunogenicity studies are currently underway in specific populations (infants, human immunodeficiency virus (HIV)-infected persons and healthy adults living in Uganda and Kenya), of which the results will become available in 2021–22. Conclusions: Available results on long-lasting immunogenicity of fractional-dose yellow fever vaccination are encouraging, although confirmation is required in larger populations including young children living in yellow fever endemic areas.

Long-Term Protection After Fractional-Dose Yellow Fever Vaccination

2018 ◽  
Vol 169 (11) ◽  
pp. 761 ◽  
Author(s):  
Anna H.E. Roukens ◽  
Karlijn van Halem ◽  
Adriëtte W. de Visser ◽  
Leo G. Visser
Keyword(s):  
Yellow Fever ◽  
Fractional Dose ◽  
Yellow Fever Vaccination

scholarly journals Fractional-Dose Yellow Fever Vaccination — Advancing the Evidence Base

2018 ◽  
Vol 379 (7) ◽  
pp. 603-605 ◽  
Author(s):  
Kirsten Vannice ◽  
Annelies Wilder-Smith ◽  
Joachim Hombach
Keyword(s):  
Yellow Fever ◽  
Evidence Base ◽  
Fractional Dose ◽  
Yellow Fever Vaccination

Long-term immunogenicity after yellow fever vaccination in immunosuppressed and healthy individuals

Vaccine ◽  
2020 ◽  
Vol 38 (19) ◽  
pp. 3610-3617
Author(s):  
J. Burkhard ◽  
A. Ciurea ◽  
C. Gabay ◽  
P. Hasler ◽  
R. Müller ◽  
...  
Keyword(s):  
Yellow Fever ◽  
Healthy Individuals ◽  
Yellow Fever Vaccination

Immunogenicity and safety of fractional dose yellow fever vaccination: A systematic review and meta-analysis

Vaccine ◽  
2020 ◽  
Vol 38 (6) ◽  
pp. 1291-1301 ◽  
Author(s):  
Chukwudi A. Nnaji ◽  
Muki S. Shey ◽  
Olatunji O. Adetokunboh ◽  
Charles S. Wiysonge
Keyword(s):  
Systematic Review ◽  
Yellow Fever ◽  
Meta Analysis ◽  
Fractional Dose ◽  
Yellow Fever Vaccination
Sign in / Sign up

Export Citation Format

Share Document